S'abonner

Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy - 04/05/16

Doi : 10.1016/S1470-2045(16)00063-2 
Jae Y Lee, MD a, , Daniel E Spratt, MD a, , Adam L Liss, MD a, b, Patrick W McLaughlin, ProfMD a, c,
a Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA 
b Agnesian Cancer Center, Fond du Lac, WI, USA 
c Assarian Cancer Center, Novi, MI, USA 

*Correspondence to: Prof Patrick W McLaughlin, University of Michigan, Assarian Cancer Center, Department of Radiation Oncology, Novi, MI 48374, USACorrespondence to: Prof Patrick W McLaughlinUniversity of MichiganAssarian Cancer CenterDepartment of Radiation OncologyNoviMI48374USA

Summary

Treatment selection for men undergoing curative treatment for prostate cancer is often a challenging decision in view of the goal of maximising cure while maintaining quality of life. Previous quality-of-life comparisons suggest that specific outcomes are associated with type of treatment (surgery vs radiation); however, the functional anatomy approach, starting with nerve-sparing prostatectomy, assumes that quality-of-life outcomes are established by anatomic preservation. Emerging applications of the functional anatomy approach for prostate radiation will ultimately allow for individualised treatments that address the normal tissue variants visible on MRI. Such approaches will encompass all essential functions affected by treatment including genitourinary, rectal, and sexual functions. In this Review, we outline the current techniques in functional anatomy-based preservation related to sexual outcomes, and outline the capacity of vessel-sparing radiotherapy to preserve sexual function in 90% of patients at the 5 year follow-up while maintaining excellent cure rates.

Le texte complet de cet article est disponible en PDF.

Plan


© 2016  Elsevier Ltd. Tous droits réservés.
Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 17 - N° 5

P. e198-e208 - mai 2016 Retour au numéro
Article précédent Article précédent
  • Ethical issues of clinical trials in paediatric oncology from 2003 to 2013: a systematic review
  • Jean-Claude K Dupont, Kathy Pritchard-Jones, François Doz
| Article suivant Article suivant
  • Under-reporting of harm in clinical trials
  • Bostjan Seruga, Arnoud J Templeton, Francisco Emilio Vera Badillo, Alberto Ocana, Eitan Amir, Ian F Tannock

Déjà abonné à cette revue ?